BCL2 and prostate carcinoma: This suggested that hyper-activation of STAT5 signaling per se may not act as an oncogene in the prostate, but it could tweak prostate cancer progression in a more proto-oncogenic role driving e.g., enhanced Myc, Bcl2 or D type cyclin family member expressions.